Business Description
Cyclopharm Ltd
NAICS : 334510
SIC : 3845
ISIN : AU000000CYC5
Description
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.77 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -1.31 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 7.15 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.9 | |||||
| 3-Year EBITDA Growth Rate | 18.2 | |||||
| 3-Year EPS without NRI Growth Rate | 13.6 | |||||
| 3-Year FCF Growth Rate | 12.5 | |||||
| 3-Year Book Growth Rate | 17.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.86 | |||||
| 9-Day RSI | 30.3 | |||||
| 14-Day RSI | 38.51 | |||||
| 6-1 Month Momentum % | -13.46 | |||||
| 12-1 Month Momentum % | -12.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.48 | |||||
| Quick Ratio | 2.32 | |||||
| Cash Ratio | 1.35 | |||||
| Days Inventory | 314.86 | |||||
| Days Sales Outstanding | 96.7 | |||||
| Days Payable | 177.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.56 | |||||
| Forward Dividend Yield % | 0.56 | |||||
| 5-Year Yield-on-Cost % | 0.56 | |||||
| 3-Year Average Share Buyback Ratio | -5.4 | |||||
| Shareholder Yield % | 0.65 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.07 | |||||
| Operating Margin % | -38.06 | |||||
| Net Margin % | -17.85 | |||||
| FCF Margin % | -29.37 | |||||
| ROE % | -13.6 | |||||
| ROA % | -9.74 | |||||
| ROIC % | -45.71 | |||||
| ROC (Joel Greenblatt) % | -27.24 | |||||
| ROCE % | -10.52 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.16 | |||||
| PB Ratio | 5.1 | |||||
| Price-to-Tangible-Book | 6.25 | |||||
| EV-to-EBIT | -38.44 | |||||
| EV-to-EBITDA | -49.63 | |||||
| EV-to-Revenue | 6.08 | |||||
| EV-to-Forward-Revenue | 6.66 | |||||
| EV-to-FCF | -20.7 | |||||
| Price-to-Median-PS-Value | 1.1 | |||||
| Price-to-Net-Current-Asset-Value | 9.72 | |||||
| Earnings Yield (Greenblatt) % | -2.6 | |||||
| FCF Yield % | -4.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyclopharm Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 26.339 | ||
| EPS (TTM) (A$) | -0.051 | ||
| Beta | 1.09 | ||
| Volatility % | 45.16 | ||
| 14-Day RSI | 38.51 | ||
| 14-Day ATR (A$) | 0.019116 | ||
| 20-Day SMA (A$) | 1.783 | ||
| 12-1 Month Momentum % | -12.2 | ||
| 52-Week Range (A$) | 1.715 - 3.15 | ||
| Shares Outstanding (Mil) | 94.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyclopharm Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclopharm Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyclopharm Ltd Frequently Asked Questions
What is Cyclopharm Ltd(ASX:CYC)'s stock price today?
The current price of ASX:CYC is A$1.75. The 52 week high of ASX:CYC is A$3.15 and 52 week low is A$1.72.
When is next earnings date of Cyclopharm Ltd(ASX:CYC)?
The next earnings date of Cyclopharm Ltd(ASX:CYC) is .
Does Cyclopharm Ltd(ASX:CYC) pay dividends? If so, how much?
The Dividend Yield %  of Cyclopharm Ltd(ASX:CYC) is 0.56% (As of Today), Highest Dividend Payout Ratio of Cyclopharm Ltd(ASX:CYC) was 0.67. The lowest was 0.06. And the median was 0.36. The  Forward Dividend Yield % of Cyclopharm Ltd(ASX:CYC) is 0.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers